David Lebovitz

Stock Analyst at Citigroup

(2.06)
# 1071
Out of 5,344 analysts
127
Total ratings
74.55%
Success rate
12.97%
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
BMRN Biomarin Pharmaceuti...
Maintains: Neutral
82 78
57.53 35.58% 4 May 2, 2025
ALNY Alnylam Pharmaceutic...
Maintains: Strong Buy
338 351
290.77 20.71% 31 Mar 21, 2025
MDGL Madrigal Pharmaceuti...
Maintains: Strong Buy
378 469
267.39 75.4% 4 Feb 27, 2025
CRNX Crinetics Pharmaceut...
Maintains: Strong Buy
70 74
29.76 148.66% 2 Nov 14, 2024
MIRM Mirum Pharmaceutical...
Maintains: Strong Buy
37 38
44.01 -13.66% 1 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Sell
29 17
45.94 -63% 5 Oct 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
111 92
101.46 -9.32% 6 Feb 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
57 54
62.36 -13.41% 5 Aug 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
408 372
n/a n/a 5 May 14, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
11 10
n/a n/a 5 May 7, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
38 35
32.97 6.16% 6 May 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
16 17
1.5 1033.33% 11 Apr 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
12 11
0.56 1864.29% 7 Feb 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
193 220
n/a n/a 5 Feb 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
50 500
n/a n/a 2 Dec 7, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
45 44
n/a n/a 10 Nov 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
194 199
161.93 22.89% 11 Nov 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
510 480
4.59 10357.52% 2 Nov 3, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
27 26
n/a n/a 2 Aug 13, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
119 129
n/a n/a 3 Mar 6, 2018